Rosacea is a common chronic inflammatory skin disease that affects the blood vessels of the facial skin and sebaceous glands. Primary symptoms include transient or persistent erythema, papules, and pustules, all of which largely affect the central part of the face. Long-term patients may develop dark red plaques or rhinophyma (a typical uneven thickening of the skin of the nose) due to hyperplasia.
According to the Expert Committee of the National Rosacea Society, rosacea is classified as mild, moderate or severe depending on the severity of the lesions and symptoms. Prolonged course of the disease, tendency to relapse, associated changes in complexion, skin ulceration and scarring tend to have a detrimental effect on the physical, mental and social health of patients.
Primary treatments for rosacea currently include anti-inflammatory, antipruritic and antiparasitic agents, as well as vasomotor regulation. Modern treatments for rosacea are mainly aimed at alleviating the syndrome, improving the quality of life of patients and preventing the progression of the disease. However, they are not completely effective, possibly due to the lack of a clear understanding of the pathogenetic mechanisms of rosacea.
Today we actively use a combination of fibroblasts and exosomes + additional procedures for preparing facial skin for treatment in the treatment of rosacea. This treatment can almost always achieve significant improvements, even in fairly advanced cases of the disease. What does this combination of stem cells (fibroblasts) and exosomes provide?
1. Elimination of inflammatory processes in all layers of the skin that were associated with the onset of the disease
2. Improving the morphological processes of the skin: nutrition, hydration, regeneration
3. Regulation of the immune response and cellular metabolism
4. Improving the quality of small vessels: restoring their ability to contract, to be toned, to be elastic
5. The ability to restore damaged layers of the epidermis due to rosacea
A total of 1204 people (966 women (80.23%) and 238 men (19.77%)) with rosacea were included in the present study. The mean age of the patients was 32.1 years (range, 18–60 years); The mean disease duration was 3.5 years (range, 0.1–20.0 years). After treatment with fibroblast + exosome therapy for 7 days, all patients experienced varying degrees of improvement based on the level of rosacea pathology they had. Pathological symptoms of rosacea included superficial dermal tissue necrosis, caseous necrosis, and the formation of granuloma structures. Current research has demonstrated that the therapy can effectively restore the pathological structure of rosacea tissue, eliminate the symptoms of burning, flushing, uncontrollable redness, skin hypersensitivity, tingling, allergy reactions, etc.
